

Immunomodulatory And Carcinopreventer Activities of Coffee and Caffeine

Meir Djaldetti

Laboratory for Immunology and Hematology Research, Rabin Medical Center, Hasharon Hospital, Petah-Tiqva, the Sackler School of Medicine, Tel-Aviv University, Ramat Aviv, Israel.

***Corresponding Author:** Meir Djaldetti, Laboratory for Immunology and Hematology Research, Rabin Medical Center, Hasharon Hospital, Petah-Tiqva, the Sackler School of Medicine, Tel-Aviv University, Ramat Aviv, Israel.

Received date: September 18, 2023; **Accepted date:** September 29, 2023; **Published date:** October 09, 2023

Citation: Meir Djaldetti, (2023), Immunomodulatory and Carcinopreventer Activities of Coffee and Caffeine, *J, Biotechnology and Bioprocessing*, 4(6); DOI:10.31579/2766-2314/120

Copyright: © 2023, Meir Djaldetti. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The energizing effect of a cup of coffee combined with its distinctive flavor and test are well known and highly regarded. These coffee characteristics are due to a number of polyphenols, the principal one being caffeine. The usefulness of coffee as a potential adjuvant in medicine is increased when the health benefits of coffee drinking are added to a list of chronic disorders, such as the prevention of cancer and chronic inflammation. Consideration is warranted given the importance of chronic inflammation as a herald of cancer development and the immunomodulatory effects of caffeine and coffee on immunological and cancer cells. In this regard, caffeine's ability to alter the release of inflammatory cytokines by cancer cells as well as peripheral blood and tumor microenvironment mononuclear cells plays a critical role in the tumor development. The ways coffee or caffeine may exert carcinoprevention and particularly their impact on the cross talk between immune and cancer cells is the purpose of the present review.

Key Words: coffee; caffeine; immunity; cytokines; cancer; chemoprevention

Introduction

The world's widespread use of coffee can be easily explained by the aroma, the taste, and the comfort it brings after drinking. Furthermore, coffee's health advantages have long been known to exist. In addition to providing pleasure, coffee has beneficial effects on the progression of chronic diseases such type II diabetes, cardiovascular, gastrointestinal, and liver ailments as well as chronic inflammation [1,2]. Coffee drinkers showed lower levels of inflammatory markers such as CX3CL1, CCL4/MIP-1 β , IFN γ and FGF-2 [3]. Caffeine (CA) is the most significant of the several polyphenols found in coffee; there fore investigations are typically conducted using CA alone or in combination with other polyphenols or medications. Treatment of PBMC with CA reduced T-cell proliferation and suppressed IL-2, IL-4, IL-5, IL-10 and IFN γ production [4]. Those and other studies [5] indicate that CA exerts a significant anti-inflammatory activity. In addition, frequent coffee consumption was associated with a decreased death rate and a lower risk of cancer in a large sample of both men and women. [6]. Comprehensive meta-analyses showed that 3-4 cups of coffee consumption per day is linked with a decreased risk of breast, colorectal, endometrial and prostate cancer [7, 8]. However, according to some studies the relationship between coffee and cancer prevention is less evident with the exception of hepatocellular carcinoma and the risk of breast cancer in postmenopausal women mostly in those carrying a BRCA1 mutation. [9, 10]. The type and method of coffee

beans cultivation, the time of coffee brewing, the amount of beverages consumed daily, the duration of its use, and individual behaviors could all be factors in the disparity in the studies' findings. Given the close link between chronic inflammation and the development of cancer, the protective impact of coffee drinking on reducing the risk of cancer deserves attention [11]. Reviewing the link between the immunomodulatory capacity of coffee and CA and their carcinopreventive effect was the goal of the current study.

Anti-inflammatory and immunomodulatory effects of CA

Despite the fact that there have been many in vitro studies exploring the immunomodulatory effects of CA, investigations using both animal models and humans are infrequent [5]. In two out of five studies of coffee trials reviewed by Pavia et al. [12] CA increased the anti-inflammatory IL-10 production. Notably, the mode and the degree of PBMC stimulation affect the impact of CA on cytokine generation. Thus, non-stimulated PBMC incubated with CA did enhance IL-1 production but not that of IL-6, IL-10, or TNF, whereas PBMC stimulated by co-incubation with HT-29 or RKO colon cancer cells significantly raised the production of all of them, including IL-1ra and IFN [13]. CA induced a decreased secretion of IL-1 β and IL-18 secretion in LPS stimulated human monocytic leukemia derived macrophages due to inhibited NLRP3 inflammasome activation [14].

Macrophages stimulated with conditioned medium of mesenchymal stem cells treated with CA showed increased phagocytic capacity, inhibited ROS and NO expression compared to macrophages treated with conditioned medium alone [15]. Six mg/kg body mass of CA supplemented to athletes before exercise increased plasma concentration of IL-6, IL-10 and IL-12 levels without having any impact on PBMC production of these cytokines [16]. Interestingly, different subpopulations of human macrophages respond in a different way to coffee and CA. In contrast to macrophages activated by GM-CSF, coffee was able to promote the secretion of IL-8, IL-6, and IL-1 β in macrophages treated with macrophage colony-stimulated factor. TNF-generation, however, was reduced in both cell types [17]. It appears that how coffee is brewed and consumed affects its ability to reduce inflammation. According to Castaldo et al. [18], brewed coffee contains more polyphenols and has higher anti-oxidant activity on HT-29 cells after simulated gastrointestinal intake, than non-digested samples. Additionally, the expression of the NF-kB p65 subunit and the pro-inflammatory cytokine IL-6 were inhibited by digested coffee samples, whereas the production of the anti-inflammatory cytokine IL-10 was increased. Notably, higher CA doses suppress the macrophage and NK cells immune activity by a decreased synthesis of the anti-inflammatory cytokines, as well as TLR1, TLR2, and TLR4 receptors, while lower doses promoted their secretion [5]. One cup of coffee's worth of CA exposure to PBMC caused a downregulation of the inflammatory pathways STAT1, TNF, and IFN as well as lower levels of several pro-inflammatory cytokines. [19].

Caffeine and cancer development




Figure 1: Caffeine affects the proliferation and viability of cancer cells (C) by a mitotic cycle arrest (M), increased apoptosis (A) and phagocytosis (P) and necrosis (N). In addition it modulates the immune activity of the mononuclear cells.

Digestive tract cancers

Esophageal cancer

The effect of CA on the digestive tract malignancies has attracted researchers' attention, but it appears that CA's efficacy in preventing esophageal cancer is uncertain. In a retrospective analysis of patients with Barrett's esophagus, CA was found to be a risk factor for developing into esophageal cancer along with other factors like age and abdominal obesity [25]. In vitro studies have shown that CA inhibits the proliferation rate of esophagus squamous carcinoma KYSE-30 cells in a dose-dependent matter [26]. On the other hand, a meta-analysis of a large sample of coffee drinkers revealed that East Asians, but not Euro-Americans, were protected from esophageal cancer by coffee [27].

Gastric cancer

The prevalence of coffee consumption raises the potential of a connection between coffee intake and the risk of gastric cancer. Studies on the subject

Coffee and its polyphenols gained the title of chemopreventers by modulating the immune system, the course of chronic inflammation and the production of anti-inflammatory cytokines. Montenegro et al. [20] reported that coffee prompted prostate cancer prevention by lowering the production of the inflammatory mediators IL-6, IL-8, TNF α , C reactive protein, and modulation of the NF-kB pathway. In a carcinogen-induced model, CA was found to inhibit immunological mechanisms that contribute to the development of cancer by increasing the infiltration of CD8+T lymphocytes while decreasing that of CD+CD25+ regulatory cells. The PD-1 activity decreased in each group. IFN γ - and IL-6 production was boosted by CA combined with anti-PD1mAb and increased anti-tumor activity against B16F10 melanoma cells [21]. Acting on cytokine receptors, CA amplified the antitumor properties of CD4+ and CD8+ T lymphocytes, and increased the activity of macrophages and natural killer cells, thus reducing the development of colorectal cancer cells [22]. The production of the pro-inflammatory cytokines IL-6, IL-12, and TNF α was found to be reduced in a mouse colon carcinogenesis model when CA and its ester, chlorogenic acid, were administered together as opposed to when the coffee polyphenols were given alone. Additionally, the production of non-coding miR molecules was modified, thus reducing cancer development [23]. Tryptophan-induced coffee extracts prevented the production of IL-8, IL-12, TNF α and IL1- β in colon carcinoma HT-29 cells [24]. CA affects cancer cells in a variety of ways, including mitotic arrest, autophagocytosis, enhanced macrophage phagocytosis, and necrosis as depicted in Figure. 1.

failed to demonstrate an association between coffee beverage and carcinogenesis [28]; moreover, reports suggested that coffee polyphenols and in particular CA may lower the risk of gastric cancer development [29,30]. CA treatment of MGC-803 and SGC-7901 gastric cancer cells resulted in lowered growth and enhanced apoptosis due to activation of the caspase-9/-3 pathway, enzymes actively involved in the apoptotic progression [31]. In the same type of cells CA suppressed cell proliferation and migration and prompted autophagy through PTEN activation and PI3K/Akt/mTOR pathway inhibition [32]. CA had the ability to boost the effectiveness of gastric anti-cancer medications. The combination of CA with cisplatin significantly improved cisplatin cytotoxicity on STKM-1 gastric cancer cells [33] and the survival time of STKM-1 cancer bearing mice compared to the effect of each of the substances alone [34].

Colorectal cancer

Coffee intake was found to be inversely associated with progression and metastasis of colorectal cancer [35] and with a reduced the risk of its

development by about 13% [23]. According to prospective studies, drinking 2-4 cups or more per day dramatically reduced stage III colorectal cancer risk and mortality [36-38]. CA's effect on the proliferation and apoptosis of the malignant cells of colorectal cancer bearing mice was greatly enhanced when combined with another coffee polyphenol, i.e. chlorogenic acid [23]. Emile et al. [39] conclude that further research is needed to determine whether coffee drinking has any influence on colorectal cancer in a recent review that included 14 systematic studies on the topic.

Hepatocellular carcinoma

Hepatocellular carcinoma risk has been shown to be decreased by coffee drinking [40-42]. CA supplementation significantly increased the apoptotic effect of 5-fluorouracil and decreased the growth of malignant cells, which was attributed to the activation of the pro-apoptotic Bcl-2 and Bcl-xL proteins and amplified PARP enzyme cleavage [43]. A further route by which CA reduces hepatocellular carcinoma cells is PI3K/Akt inhibition [44]. Incubation of HrpG2 and Huh7 hepatocellular carcinoma cells with CA at doses 0-600 μ M reduced proliferation, migration and invasion via Akt signaling pathway. When HrpG2 carcinoma bearing mice were fed with CA the number and progression of the tumors was reduced [45].

Breast cancer

There isn't much clear evidence from studies on the role of coffee and CA in preventing breast cancer. Analyses on a large number of patients failed to demonstrate an association between coffee consumption and incidence of invasive cancer risk in postmenopausal women [46-48]. Lafraconi et al. [49] reported that four cups of coffee a day may reduce the incidence of breast cancer in those patients by 10%. Treatment of MCF-7 and MDA-MB-231 breast cancer cells with various doses of CA caused an inhibited cell proliferation and viability, as well as a burst of oxidative stress. The generated reactive oxygen species (ROS) damaged the DNA in the MCF-7 cells but not in those of the MDA-MB-231 line indicating that the toxicity of CA varied depending on the subtype of cancer cells [10,50].

Genital tract cancers

Although research on the impact of CA on the development of genital tract cancer is, at best, classified as unreliable [51,52], it has been found that overall CA consumption from coffee and tea was associated with a lower risk of ovarian cancer in a case-control study done in Denmark [53]. Four cups of coffee per day were linked to a 20% lower risk of endometrial cancer, according to a meta-analysis on the topic [49]. Other cohort studies and meta-analyses support these observations [54,55]. These and additional reports [7,54] indicate that the relationship between CA and the development of genital cancer is still uncertain and additional research is advised to elucidate the situation. Likewise, the reports as for the effect of CA on ovarian cancer development are rather inconclusive. In an analysis of data comprising 44,062 individuals, Ong et al. [56] concluded that there was no link between coffee consumption and the risk of epithelial ovarian cancer, findings supported by other studies [57,58].

Lung cancer

Considering the habit of coffee drinking with cigarette smoking the association of CA intake with lung cancer development is difficult to assess. Guertin et al. [59], based on a sizable group of individuals have concluded that six cups of coffee per day was positively associated with the occurrence of lung cancer. However an adjustment regarding smoking attenuated the linkage between coffee consumption and cancer development. Studies done in vitro showed more encouraging results. In NCI-H23 lung cancer cells, p-FaK and p-Akt kinase activity were reduced, metastasis-promoting integrins were downregulated, and the cell cycle was arrested at the G0/G1 phase [60]. Claudin-2, a protein that is abundantly expressed in A549 lung cancer cells, was significantly downregulated by CA together with Nrf 2 factor. Additionally, CA boosted the doxorubicin cytotoxicity [61]. CA alone and in combination with artemisinin, a product of *Artemisia annua*, caused an

attenuation of the tumor lesions in several organs in mice with dimethylbenzene-anthracene induced cancer by reducing P53 expression and nitric oxide levels [62].

Prostate cancer

There is conflicting evidence about CA's relationship to the risk of prostate cancer. Prostate cancer cells PC-3 and DU145 that have been treated with CA had significantly less ability to proliferate and spread. Additionally, cohort studies conducted concurrently with the in vitro tests found that men who drank more than three cups of coffee per day had a 53% lower risk of developing prostate cancer than those who drank 0-2 cups. [63]. In a population case control study, Geybels et al. [64] attained comparable outcomes. Notably, when combined with atorvastatin, the effect of CA on the migratory capacity, invasion, and death of prostate cancer cells was dramatically enhanced [65]. A combination of CA and atorvastatin decreased the activity of phosphorylated Akt and Erk1/2, two proteins crucial for the survival of prostate cancer cells, and increased the anti-apoptotic gene Bcl-2. [65].

Malignant melanoma

Patients studies revealed that high coffee consumption or CA intake - \geq 393 mg/day as opposed to $<$ 60 mg/day was negatively associated with the risk of malignant melanoma [66], data that were later supported by case control analyses [67,68]. Administration of 100 mg/kg/body weight of CA to mice bearing B16F10 melanoma tumors with lung metastases showed a definitive reduction of spreading and tumor volume [69]. Tyrosinase expression, a prerequisite for the synthesis of melanin, was reduced in melanoma-initiating cells treated with CA, as was the secretion of the cytokines IL-1, IL-10, MIP-1, and IMP-1, which are known to promote inflammation [70]. Synergistic treatment of B16F10 melanoma cells with doxorubicin and CA resulted in a significant reduced tumor growth most likely by inhibiting the adenosine-A2A receptor pathway that controls inhibitory cytokines [71], indicating that A2A receptor antagonists may be another approach for preventing the development of cancer [72].

Other cancers

Although it has been advised to further examine the potential benefit of coffee as a preventer of renal cancer, based on meta-analyses [73], earlier studies have revealed that consumption of coffee was inversely associated with the incidence of renal carcinoma [74,75].

CA affects the cross between immune and cancer cells.

The monocytes/macrophages and lymphocytes with all their subtypes in the peripheral blood and the tumor microenvironment play a crucial role in maintaining chronic inflammation prior to carcinogenesis. In this regard the role of inflammatory cytokines in the proceeding of cancer development has been thoroughly studied [76]. It has been demonstrated that TGF- β , TNF, and a number of interleukins, including IL-6, IL-10, IL-12, IL-17, and IL-23, are involved in the growth and proliferation of cancer cells [77]. Certain interleukins such as IL-5, IL-6 and IL-27 enhance cancer spread and suppress apoptosis [78]. Cytokines generated by tumor cells may promote tumor development and migration as well to stimulate tumor microenvironment for production of pro-inflammatory cytokines such as IL-6 and IL-8 [79]. Tumor cell-produced TGF, TNF, IL-6, and IL-12 may stimulate the generation of pro- and anti-inflammatory cytokines by macrophages and mononuclear cells [76], inciting the existence of an immune cross-talk between cancer, innate immune cells and those in the tumor microenvironment [78,80,81]. Chen et al. [82] reported that MDA-MB-231, MCF-7, T-47D and BT-474 human breast cancer cells release a great number of inflammatory cytokines resulting in a cross-talk between immune and cancer cells. Some of them, such as IL-1 β are closely connected with the spreading capacity of breast cancer cells to the bones that could be inhibited by drug administration [83]. Alteration of the cross-talk between immune and cancer cells induced by CA has been reported by Bessler et al. [13].




Figure 2: Caffeine affects the cross-talk between macrophages (Ma) and lymphocytes (Ly) and cancer cell Ca) stimulating the cells for pro-inflammatory (red stars) and anti-inflammatory (blue stars) cytokine production.

Figure. 2 illustrates the crucial interactions between mononucleus and cancer cells. TGF- β performs two functions in cancer development: in the early stages of it induces apoptosis and interact with the cell cycle; in the later stages, it stimulates tumor migration and metastasis [84, 85]. Studies have shown that CA may impair tumor progress by modulating immune responses through inhibition of cAMP-phosphodiesterase, inhibition of adenosine receptors and modulation of HIF-1 α , IL-8 and VEGF expression by cancer cells [86]. CA decreased tumor incidence and growth by inhibition of PD1 receptors in CD4+CD5+ regulatory T lymphocytes [21].

Conclusion

Taken together, the findings from meta-analyses, prospective and laboratory research indicate that coffee and CA exert a protective effect against significant types of malignancies through a variety of molecular mechanisms. Immunomodulation expressed by decreased pro-inflammatory interleukins production and enhanced activity of the anti-inflammatory ones is a key factor in the regulation of tumor microenvironment and cancer development [23]. Moreover, it has been proposed that CA may act as an additive to anticancer medications by targeting the pro-inflammatory cytokines [87]. The data presented support the assertion made in the majority of publications on the subject that further research is required to elucidate the mechanisms of CA carcinopreventer effect and to introduce it as an important adjuvant to anticancer drugs.

Conflicts of interest:

none

Ethical approval:

not applicable

Funding:

none

List of Abbreviations

A2aR: protein recognition adenosine receptor

BCL-2: cell cycle regulator

CX3CL1: transmembrane adhesion protein

FGF: fibroblast growth factor

GM-CSF: granulocyte macrophage colony stimulating factor

HIF-1 α Hypoxia-inducible factor 1-alpha,

MIP: macrophage inflammatory proteins

mTOR: mammalian rapamycin target

NLRP: pattern recognition adapter

NO: nitric oxide

Nrf2: nuclear factor erythroid 2 related factor

pAk7: protein kinase

PARP: poly(ADP-ribose) polymerase

PBMC: peripheral blood mononuclear cells

pFaK: focal adhesion kinase

PI3K: Akt phosphoinositide 3-kinase

PTEN: phosphatase tensin homologue

ROS: reactive oxygen species

STAT: Signal transducers and activators of transcription

TLR: immune recognition receptor

References

1. Nieber K. (2017). The impact of coffee on health. *Planta Med*, 83: 1256-63.
2. Safe S, Kothar J, A Hailemariam, et al. (2023). Health benefits of coffee consumption for cancer and other diseases and mechanisms of action. *Int. J. Mol. Sci.* 24: 2706.
3. Loftfield E, Shiels MS, Graubard BI, et al. (2015). Associations of coffee drinking with systemic immune and inflammatory markers. *Cancer Epidemiol Biomarkers Prev*, 24: 1052-1060
4. Horrigan LA, Kelly JP, Connor TJ. (2006). Immunomodulatory effects of caffeine: friend or foe? *Pharmacol Ther*, 111: 877-892.

5. Al Reef T, Ghanem E. (2018). Caffeine: Well-known as psychotropic substance, but little as immunomodulator. *Immunobiology*, 223: 818-825.
6. Sado J, Kitamura T, Kitamura Y, et al. (2017). Three-Prefecture Cohort Study Group. Association between coffee consumption and all-sites cancer incidence and mortality. *Cancer Sci*, 2017; 108: 2079-2087.
7. Grosso G, Godos J, Galvano F, et al. (2017). Coffee, caffeine, and health outcomes: An umbrella review. *Annu Rev Nutr*, 37: 131-156.
8. Di Maso M, Boffetta P, Negri E, et al. (2021). Caffeinated coffee consumption and health outcomes in the US population: A dose-response meta-analysis and estimation of disease cases and deaths avoided. *Adv Nutr*, 12: 1160-1176.
9. Pauwels EKJ, Volterrani D. (2021). Coffee consumption and cancer risk: An assessment of the health implications based on recent knowledge. *Med Princ Pract*, 30: 401-411.
10. Nehlig A, Reix N, Arbogast P, et al. (2021). Coffee consumption and breast cancer risk: a narrative review in the general population and in different subtypes of breast cancer. *Eur J Nutr*, 60: 1197-1235
11. Mantovani A, Allavena P, Sica A, et al. (2008). Cancer-related inflammation. *Nature* 454: 436-44.
12. Paiva C, Beserra B, Reis C, et al. (2019). Consumption of coffee or caffeine and serum concentration of inflammatory markers: A systematic review. *Crit Rev Food Sci Nutr*, 59: 652-663.
13. Bessler H, Salman H, Bergman M, et al. (2012). Caffeine alters cytokine secretion by PBMC induced by colon cancer cells. *Cancer Invest*, 30: 87-91.
14. Zhao W, Ma L, Cai C, et al. (2019). Caffeine inhibits NLRP3 inflammasome activation by suppressing MAPK/NF- κ B and A2aR signaling in LPS-induced THP-1 macrophages. *Int J Biol Sci*, 15:1571-1581.
15. Shushtari N, Abtahi Froushani SM. (2017). Caffeine augments the instruction of anti-inflammatory macrophages by the conditioned medium of mesenchymal stem cells. *Cell J*, 19: 415-24.
16. Tauler P, Martinez S, Martinez P, et al. (2016). Effects of caffeine supplementation on plasma and blood mononuclear cell interleukin-10 levels after exercise. *Int J Sport Nutr Exerc Metab*. 26: 8-16
17. Kovács EG, Alatshan A, Budai MM, et al. (2021). Caffeine has different immunomodulatory effect on the cytokine expression and NLRP3 inflammasome function in various human macrophage subpopulations. *Nutrients*, 13, 2409.
18. Castaldo L, Toriello M, Sessa R, et al. (2021). Antioxidant and anti-inflammatory activity of coffee brew evaluated after simulated gastrointestinal digestion. *Nutrients*, 13, 4368.
19. Iris M, Tsou PS, Sawalha AH. (2018). Caffeine inhibits STAT1 signaling and downregulates inflammatory pathways involved in autoimmunity. *Clin Immunol*, 192: 68-77.
20. Monkkonen T, Debnath J. (2018). Inflammatory signaling cascades and autophagy in cancer. *Autophagy*, 14:190-198.
21. Tej GNVC, Neogi K, Nayak PK. (2019). Caffeine-enhanced anti-tumor activity of anti-PDI monoclonal antibody. *Int Immunopharmacol*, 77: 106002.
22. Cui WQ, Wang ST, Pan D, et al. (2020). Caffeine and its main targets of colorectal cancer. *World J Gastrointest Oncol*, 12: 149-172.
23. Bartolomeu AR, Romualdo GR, Lisón CG, et al. (2022). Caffeine and chlorogenic acid combination attenuate early-stage chemically induced colon carcinogenesis in mice: involvement of oncomiR miR-21a-5p. *Int J Mol Sci*, 23: 6292.
24. Castaldo L, Toriello M, Izzo L, et al. (2022). Effect of different coffee brews on tryptophan metabolite-induced cytotoxicity in HT-29 Human colon cancer cells. *Antioxidants (Basel)*, ; 11: 2458.
25. Kambhampati S, Tieu AH, Lubber B, et al. (2020). Risk factors for progression of Barrett's esophagus to high grade dysplasia and esophageal adenocarcinoma. *Sci Rep*, 2020; 10: 4899.
26. Tonkaboni A, Lotfibakhshaiesh N, Danesh P, et al. (2021). Evaluation of inhibitory effects of caffeine on human carcinoma cells. *Nutr Cancer*, 73: 1998-2002.
27. Zhang J, Zhou B, Hao C. (2018). Coffee consumption and risk of esophageal cancer incidence: A meta-analysis of epidemiologic studies. *Medicine (Baltimore)*, 97e: 0514
28. Martimianaki G, Bertuccio P, Alicandro G, et al. (2022). Coffee consumption and gastric cancer: a pooled analysis from the stomach cancer Pooling Project consortium. *Eur J Cancer Prev*, 31: 117-127.
29. Ainslie-Waldman CE, Koh WP, Jin A, et al. (2014). Coffee intake and gastric cancer risk: the Singapore Chinese health study. *Cancer Epidemiol Biomarkers Prev*, 23: 638-647.
30. Romualdo GR, Rocha AB, Vinken M, et al. (2019). Drinking for protection? Epidemiological and experimental evidence on the beneficial effects of coffee or major coffee compounds against gastrointestinal and liver carcinogenesis. *Food Res Int*, 123: 567-589
31. Liu H, Zhou Y, Tang L. (2017). Caffeine induces sustained apoptosis of human gastric cancer cells by activating the caspase 9/caspase 3 signaling pathway. *Mol Med Rep*, 16: 2445-2454.
32. Liu H, Song J, Zhou Y, et al. (2019). Methylxanthine derivatives promote autophagy in gastric cancer cells targeting PTEN. *Anticancer Drugs*, 30: 347-355.
33. Takahashi M, Yamamoto Y, Hatori S, et al. (1998). Enhancement of CDDP cytotoxicity by caffeine is characterized by apoptotic cell death. *Oncol Rep*, 5: 53-66.
34. Takahashi M, Yanoma S, Yamamoto Y, et al. (1998). Combined effect of CDDP and caffeine against human gastric cell line in vivo. *Anticancer Res*. 18(6A): 4399-4401.
35. Mackintosh C, Yuan C, Ou FS, et al. (2020). Association of coffee intake with survival in patients with advanced or metastatic colorectal cancer. *JAMA Oncol*, 6: 1713-1721.
36. Um CY, McCullough ML, Guinter MA, et al. (2020). Coffee consumption and risk of colorectal cancer in the Cancer Prevention Study-II Nutrition Cohort. *Cancer Epidemiol.*, 67: 101730.
37. Hu Y, Ding M, Yuan C, et al. (2018). Association between coffee intake after diagnosis of colorectal cancer and reduced mortality. *Gastroenterology*. 154: 916-26. e9.
38. Guercio BJ, Sato K, Niedzwiecki D, et al. (2015). Coffee intake, recurrence, and mortality in stage III colon cancer: results from CALGB 89803 (Alliance). *J Clin Oncol*, 33: 3598-607.
39. Emile SH, Barsom SH, Garoufalia Z, et al. (2023). Does drinking coffee reduce the risk of colorectal cancer? A qualitative umbrella review of systematic reviews. *Tech Coloproctol*,
40. Kennedy OJ, Roderick P, Buchanan R, et al. (2017). Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis. *BMJ Open*, 7e, 013739.
41. Bai K, Cai Q, Jiang Y, et al. (2016). Coffee consumption and risk of hepatocellular carcinoma: a meta-analysis of eleven epidemiological studies. *Onco Targets Ther*, 9: 4369-4375
42. Inoue M, Tsugane S. (2019). Coffee drinking and reduced risk of Liver Cancer: update on epidemiological findings and potential mechanisms. *Curr Nutr Rep*, 8 :182-186.
43. Wang Z, Gu C, Wang X, et al. (2019). Caffeine enhances the anti-tumor effect of 5-fluorouracil via increasing the production

- of reactive oxygen species in hepatocellular carcinoma. *Med Oncol*, 36: 97.
44. Edling CE, Selvaggi F, Ghonaim R, et al. (2014). Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway. *Cancer Biol Ther*, 15: 524-32.
 45. Dong S, Kong J, Kong J, et al. (2015). Low concentration of caffeine inhibits the progression of the hepatocellular carcinoma via Akt signaling pathway. *Anticancer Agents Med Chem*, 15: 484-492.
 46. Gapstur SM, Gaudet MM, Wang Y, et al. (2020). Coffee consumption and invasive Breast cancer incidence among postmenopausal women in the cancer prevention study-II nutrition cohort. *Cancer Epidemiol Biomarkers Prev*, 29: 2383-2386.
 47. Zheng KH, Zhu K, Wactawski-Wende J, et al. (2021). Caffeine intake from coffee and tea and invasive breast cancer incidence among postmenopausal women in the Women's Health Initiative. *Int J Cancer*, 149: 2032-2044.
 48. Wang S, Li X, Yang Y, et al. (2021). Does coffee, tea and caffeine consumption reduce the risk of incident breast cancer? A systematic review and network meta-analysis. *Public Health Nutr*, 24: 6377-6389.
 49. Lafranconi A, Micek A, De Paoli P, et al. (2018). Coffee intake decreases risk of postmenopausal breast cancer: A dose-response meta-analysis on prospective cohort studies. *Nutrients*, 10: 112.
 50. Machado KL, Marinello PC, Silva TNX, et al. (2021). Oxidative stress in caffeine action on the proliferation and death of human breast cancer cells MCF-7 and MDA-MB-231. *Nutr Cancer*, 8: 1378-1388.
 51. Yang TO, Crowe F, Cairns BJ, et al. (2015). Tea and coffee and risk of endometrial cancer: cohort study and meta-analysis. *Am J Clin Nutr*, 101: 570-578.
 52. Gao Y, Zhai P, Jiang F, et al. (2022). Association between coffee drinking and endometrial cancer risk: A meta-analysis. *J Obstet Gynaecol Res*, 48: 774-795.
 53. Gosvig CF, Kjaer SK, Blaekær J, et al. (2015). Coffee, tea, and caffeine consumption and risk of epithelial ovarian cancer and borderline ovarian tumors: Results from a Danish case-control study. *Acta Oncol*, 54: 1144-1151.
 54. Zhou Q, Luo ML, Li H, et al. (2015). Coffee consumption and risk of endometrial cancer: a dose-response meta-analysis of prospective cohort studies. *Sci Rep*, 5: 13410.
 55. Arthur R, Kirsh VA, Rohan TE. (2018). Associations of coffee, tea and caffeine intake with risk of breast, endometrial and ovarian cancer among Canadian women. *Cancer Epidemiol*, 56: 75-82
 56. Ong JS, Hwang LD, Cuellar-Partida G, et al. (2018). Ovarian Cancer Association Consortium. Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. *Int J Epidemiol*, 47: 450-459.
 57. Shafiei F, Salari-Moghaddam A, Milajerdi A, et al. (2019). Coffee and caffeine intake and risk of ovarian cancer: a systematic review and meta-analysis. *Int J Gynecol Cancer*, 29: 579-84.
 58. Salari-Moghaddam A, Milajerdi A, Surkan PJ, et al. (2019). Caffeine, type of coffee, and risk of ovarian cancer: A dose-response meta-analysis of prospective studies. *J Clin Endocrinol Metab*, 104 :5349-5359.
 59. Guertin KA, Freedman ND, Loftfield E, et al. (2016). Coffee consumption and incidence of lung cancer in the NIH-AARP Diet and Health Study. *Int J Epidemiol*. 45: 929-39.
 60. Meisaprow P, Aksorn N, Vinayanuwattikun C, et al. (2021). Caffeine induces G0/G1 cell cycle arrest and inhibits migration through integrin α v, β 3, and FAK/Akt/c-Myc signaling pathway. *Molecules*, 26: 7659.
 61. Eguchi H, Kimura R, Onuma S et al. (2022). Elevation of anticancer drug toxicity by caffeine in spheroid model of human lung adenocarcinoma A549 Cells mediated by reduction in claudin-2 and Nrf2 expression. *Int J Mol Sci*, 23 :15447.
 62. Dokunmu TM, Opara SC, Imaga NA, et al. (2023). P53 gene expression and nitric oxide levels after artemisinin-caffeine treatment in breast, lungs and liver of DMBA-induced tumorigenesis. *Asian Pac J Cancer Prev*, 24: 451-458
 63. Pounis G, Tabolacci C, Costanzo S, et al. (2017). Moli-sani study investigators. Reduction by coffee consumption of prostate cancer risk: Evidence from the Moli-sani cohort and cellular models. *Int J Cancer*, 141: 72-82.
 64. Geybels MS, Neuhouwer ML, Stanford JL. (2013). Associations of tea and coffee consumption with prostate cancer risk. *Cancer Causes Control*, 24: 941-948.
 65. Wang Z, Zhang L, Wan Z, et al. (2020). Atorvastatin and caffeine in combination regulates apoptosis, migration, invasion and tumorspheres of prostate cancer cells. *Pathol Oncol Res*, 26: 209-216.
 66. Wu S, Han J, Song F, et al. (2015). Caffeine intake, coffee consumption, and risk of cutaneous malignant melanoma. *Epidemiology*, 26: 898-908.
 67. Liu J, Shen B, Shi M, Cai J. (2016). Higher Caffeinated Coffee Intake Is Associated with Reduced Malignant Melanoma Risk: A Meta-Analysis Study. *PLoS One*, 11: e0147056.
 68. Micek A, Godos J, Lafranconi A, et al. Caffeinated and decaffeinated coffee consumption and melanoma risk: a dose-response meta-analysis of prospective cohort studies. *Int J Food Sci Nutr*, 69: 417-426.
 69. Gude RP, Menon LG, Rao SG. (2001). Effect of caffeine, a xanthine derivative, in the inhibition of experimental lung metastasis induced by B16F10 melanoma cells. *J Exp Clin Cancer Res*, 20: 287-292.
 70. Tabolacci C, Cordella M, Rossi S, et al. (2021). Targeting melanoma-initiating cells by caffeine: in silico and in vitro approaches. *Molecules*. 26: 3619.
 71. Yerragopu AK, Vellapandian C. (2023). Chemoimmunotherapy with doxorubicin and caffeine combination enhanced ICD induction and T-cell infiltration in B16F10 melanoma tumors. *J Biochem Mol Toxicol*, 37e: 23327.
 72. Eini H, Frishman V, Yulzari R, et al. (2015). Caffeine promotes anti-tumor immune response during tumor initiation: Involvement of the adenosine A2A receptor. *Biochem Pharmacol*, 98: 110-118.
 73. Wijarnpreecha K, Thongprayoon C, Thamcharoen N, et al. (2017). Association between coffee consumption and risk of renal cell carcinoma: a meta-analysis. *Intern Med J*. 47: 1422-32.
 74. Nkondjock A. (2009). Coffee consumption and the risk of cancer: an overview. *Cancer Lett*, 277: 121-125
 75. Antwi SO, Eckel-Passow JE, Diehl ND, et al. (2017). Coffee consumption and risk of renal cell carcinoma. *Cancer Causes Control*. 28: 857-866.
 76. Candido J, Hagemann T. (2013). Cancer-related inflammation. *J Clin Immunol*. 33 Suppl 1: S79-84.
 77. Maryam S, Krukiewicz K, Haq IU, et al. (2023). Interleukins (cytokines) as biomarkers in colorectal cancer: progression, detection, and monitoring. *J Clin Med*, 12: 3127.
 78. Djaldetti M, Bessler H. (2014). Modulators affecting the immune dialogue between human immune and colon cancer cells. *World J Gastrointest Oncol*, 6: 129-138.
 79. Kartikasari AER, Huertas CS, Mitchell A, et al. (2021). Tumor-induced inflammatory cytokines and the emerging diagnostic

- devices for cancer detection and prognosis. *Front Oncol*, 11: 692142.
80. Hashimoto T, He Z, Ma WY, et al. (2004). Caffeine inhibits cell proliferation by G0/G1 phase arrest in JB6 cells. *Cancer Res*, 64: 3344-3349.
81. Atrekhany KN, Drutskaya MS, Nedospasov SA, et al. (2016). Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment. *Pharmacol Ther*, 168: 98-112.
82. Chen K, Satlof L, Stoffels G, et al. (2019). Cytokine secretion in breast cancer cells - MILLIPLEX assay data. *Data Brief*. 28: 104798.
83. Tulotta C, Lefley DV, Freeman K, et al. (2019). Endogenous production of IL1B by breast cancer cells drives metastasis and colonization of the bone microenvironment. *Clin Cancer Res*, 25: 2769-2782.
84. Syed V. (2016). TGF- β Signaling in cancer. *J Cell Biochem.*, 117: 1279-1287
85. Gu S, Feng XH. (2018). TGF- β signaling in cancer. *Acta Biochim Biophys Sin (Shanghai)*, 50: 941-949
86. Sabisz M, Skladanowski A. (2008). Modulation of cellular response to anticancer treatment by caffeine: inhibition of cell cycle checkpoints, DNA repair and more. *Curr Pharm Biotechnol*, 9: 325-336.
87. Lee HM, Lee HJ, Chang JE. (2022). Inflammatory cytokine: an attractive target for cancer treatment. *Biomedicines*, 10: 2116.



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here:

Submit Manuscript

DOI:10.31579/2766-2314/120

Ready to submit your research? Choose Auctores and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At Auctores, research is always in progress.

Learn more <https://www.auctoresonline.org/journals/biotechnology-and-bioprocessing>